During the last two decades, monoclonal antibodies have played an increasing role in the treatment of Crohn’s disease; however, therapy with tumor necrosis factor (TNF)-inhibitors is challenging due to high rates of nonresponse and secondary loss of response [3,4]. The gene discussed is TNF; the disease is Crohn disease.